글로벌 코시디오이도미코시스 약물 시장 - 업계 동향 및 2028년까지의 예측

시장 분석 및 통찰력: 글로벌 코시디오이도미코시스 약물 시장

코시디오이도미코시스 약물 시장은 2021년에서 2028년의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 상기 연구 예측 기간 동안 5.50%의 CAGR로 성장하고 있다고 분석합니다. 면역 체계가 약해진 노인 인구 증가와 코시디오이데스의 성장을 허용하는 기후 변화.

새로운 약물의 도입과 파이프라인 약물의 존재도 시장 성장을 촉진합니다. 게다가 활발한 연구 개발 노력과 증가하는 의료비 지출은 시장 성장의 기회로 작용합니다. 그러나 때때로 약물과 관련된 부작용, 엄격한 규제, 한방 요법 및 보충제의 존재는 글로벌 코시디오이도미코시스 약물 시장을 방해할 수 있습니다.

Coccidioidomycosis is also called valley fever caused by the fungal infection. The fungus responsible for causing coccidioidomycosis is known as coccidioides which lives in soil in some parts of Mexico, southwestern U.S, Central and South America. Valley fever infects people by inhalation of fungal spores present in air. The common symptoms associated with valley fever includes fatigue, headache, night sweats, muscle aches, shortness of breath among others. It is an acute term disease and has been reported to last for few days or few weeks, however some affected person experiences symptoms last longer for and infection turn to severe form. As per the CDC approximately 5 to 10% o infected people develops severe infection and thus demands effective treatment so as to lead a disease free health life. Valley fever is diagnosed by simple blood test that looks for Coccidioides antibodies or antigens, moreover skin test is also done in order to check the better functioning of immune response of a person against the Coccidioides infection. Coccidioidomycosis is usually treated by antifungal medication including fluconazole among others.

As per the publication of August 2019, this has been reported that coccidioidomycosis disease is surging at a rapid rate in American continents. The prevalence of coccidioidomycosis disease in America reported to be 42% in Guatemala, 56% in Mexico, 44% in Paraguay, 40% in Argentina among others. This increasing disease cases demands the effective and novel treatment approaches and hence expected to provide market with the lucrative growth.

This coccidioidomycosis drugs market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Coccidioidomycosis Drugs Market Scope and Market Size

Coccidioidomycosis drugs market is segmented on the basis of disease type, drugs type, by product category, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of disease type, the coccidioidomycosis drugs type market is segmented into acute coccidioidomycosis, chronic coccidioidomycosis and disseminated coccidioidomycosis.
• On the basis of drugs type, the coccidioidomycosis drugs type market is segmented into clotrimazole, econazole, miconazole, terbinafine, fluconazole, ketoconazole, amphotericin.
• On the basis of product category, the coccidioidomycosis drugs type market is segmented into prescription and over the counter.
• On the basis of end-users, the coccidioidomycosis drugs market is segmented into specialty clinics, hospitals, homecare, others.
• On the basis of distribution channel, the coccidioidomycosis drugs market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy, others. 

Coccidioidomycosis drugs Market Country Level Analysis

Coccidioidomycosis drugs market is analysed and market size information is provided by country, disease type, drugs type, product category, end-users and distribution channel as referenced above.

The countries covered in the coccidioidomycosis drugs market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, North America accounts the largest market share due to constant rise in coccidioidomycosis infections across American continent and rising demand of effective therapies. Europe accounts the second largest market share due to travel related risk factors associated with coccidioidomycosis and rising geriatric populations and increasing population of immunocompromised patients.  Asia-Pacific is expected to account for the largest market share over coming years for the coccidioidomycosis drugs market due to rising climate changes which allows favourable growth of fungal species and increasing investment for new product launches.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

코시디오이도미코시스 약물 시장은 또한 환자 분석, 예후 및 치료에 대한 자세한 시장 분석을 제공합니다. 유병률, 발생률, 사망률, 준수율은 보고서에서 사용할 수 있는 일부 데이터 변수입니다. 시장 성장에 대한 역학의 직접 또는 간접 영향 분석을 분석하여 성장 기간 동안 시장을 예측하기 위한 보다 견고하고 코호트 다변량 통계 모델을 만듭니다.

경쟁 환경 및 코시디오이도미코시스 약물 시장 점유율 분석

코시디오이도미코시스 약물 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 임상 시험 파이프라인, 제품 승인, 특허, 제품 폭과 폭, 응용 분야 우세, 기술 수명선 곡선이 있습니다. 위에 제공된 데이터 포인트는 코시디오이도미코시스 약물 시장과 관련된 회사의 초점에만 관련이 있습니다.

코시디오이도미코시스 약물 시장에서 다루는 주요 업체는 Pfizer, Brundavan Laboratories Ltd., Bazayan & Co, Beaukev Pharma Pvt. Ltd., Cipla, DEAFARMA, Glenmark Pharmaceutical Inc., Viatris Inc., Nishchem International Pvt. Ltd, SPANSULES PHARMATECH PVT. LTD., Zydus Cadila, Inabata – Pharmasynthèse, Johnson & Johnson Health Care Systems Inc., Wavelength Pharmaceuticals, Dr Reddy's Laboratories (UK) Ltd, Xellia Pharmaceuticals, Synbiotics Limited., SEBELA IRELAND LTD 등 국내 및 글로벌 업체입니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁사에 대한 경쟁 분석을 별도로 제공합니다.

SKU-60142